Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright reduced their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a research note on Monday, August 12th.

Oncternal Therapeutics Price Performance

Shares of ONCT opened at $4.16 on Friday. The firm has a market capitalization of $12.31 million, a PE ratio of -0.34 and a beta of 1.36. The company has a 50-day simple moving average of $5.98 and a two-hundred day simple moving average of $7.77. Oncternal Therapeutics has a one year low of $3.25 and a one year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last released its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same quarter in the previous year, the company earned ($3.00) EPS. Analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.